1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Dominion Diagnostics

Anonymous board for Dominion Diagnostics

Sort By:
Title
Replies Views
Last Message ↓
  1. anonymous
    Replies:
    16
    Views:
    1,999
  2. Anonymous
    Replies:
    15
    Views:
    10,386
  3. anonymous
    Replies:
    0
    Views:
    1,261
  4. Anonymous
    Replies:
    5
    Views:
    6,778
  5. anonymous
    Replies:
    2
    Views:
    3,978
  6. anonymous
    Replies:
    6
    Views:
    3,537
  7. anonymous
    Replies:
    2
    Views:
    2,394
  8. Anonymous
    Replies:
    6
    Views:
    5,663
  9. Anonymous
    Replies:
    0
    Views:
    2,934
  10. Anonymous
    Replies:
    1
    Views:
    3,407
  11. Anonymous
    Replies:
    9
    Views:
    7,676
  12. Anonymous
    Replies:
    0
    Views:
    3,459
  13. Anonymous
    Replies:
    7
    Views:
    5,097
  14. Anonymous
    Replies:
    1
    Views:
    3,447
  15. Anonymous
    Replies:
    0
    Views:
    2,951
  16. Anonymous
    Replies:
    0
    Views:
    3,283
  17. Anonymous
    Replies:
    4
    Views:
    5,414
  18. Anonymous
    Replies:
    0
    Views:
    4,363

Thread Display Options

Loading...